View More View Less
  • 1 Debreceni Egyetem, Orvos- és Egészségtudományi Centrum Belgyógyászati Intézet, Reumatológiai Tanszék Debrecen Nagyerdei krt. 98. 4032
Restricted access

Purchase article

USD  $25.00

1 year subscription (Individual Only)

USD  $1,070.00

A reumatológiában, elsősorban arthritisekben, elsődleges a korai diagnosztika és az agresszív terápia, mert ennek révén az elvárások újabb dimenziói (a fájdalomcsillapításon túl az ízületi struktúra, funkció, életminőség) nyílhatnak meg. A célzott (biológiai) terápia igen költséges kezelési mód, megjelenésével különösen fontossá vált az egyénre szabott terápia bevezetése. Számos klinikai, immunológiai és genetikai biomarker áll rendelkezésre, amelyek előre jósolhatják a hagyományos vagy biológiai betegségmódosító szerek hatékonyságát, esetleg kockázatait. A klinikai markerek közül a férfi nem, fiatalabb kor, a kezdeti alacsonyabb vagy éppen magasabb betegségaktivitás, a kombinációs kezelés, a dohányzásról leszokás jobb terápiás eredményeket adhat. Az immunológiai-gyulladásos markerek közül a C-reaktív fehérje, a szeropozitivitás, a perifériás vér és a synovium sejtösszetétele függhet össze a kezelés eredményességével. Végül, számos olyan gén vagy géncsoport ismert, amely az immunszuppresszív szerek hatékonyságát vagy biztonságosságát jelezheti. Sok esetben még kevés a vizsgálat, ellentmondóak lehetnek az eredmények, de vannak konzekvensen validált biomarkerek is. Ez optimizmussal tölthet el bennünket, hogy a reumatológiában is teret nyer a személyre szabott medicina. Orv. Hetil., 2013, 154, 483–496.

  • Rheumatologic and Physiotherapeutic Professional Board: Treatment of arthritis using synthetic and biologic disease-modifying drugs. [Reumatológiai és Fizioterápiás Szakmai Kollégium: Az arthritisek kezelése szintetikus és biológiai betegségmódosító gyógyszerekkel.] Immunol. Szemle, 2011, 3, 26–41. [Hungarian]

    'Treatment of arthritis using synthetic and biologic disease-modifying drugs. [Reumatológiai és Fizioterápiás Szakmai Kollégium: Az arthritisek kezelése szintetikus és biológiai betegségmódosító gyógyszerekkel.] ' (2011 ) 3 Immunol. Szemle : 26 -41.

    • Search Google Scholar
  • Isaacs, J. D., Ferraccioli, G.: The need for personalised medicine for rheumatoid arthritis. Ann. Rheum. Dis., 2011, 70, 4–7.

    Ferraccioli G. , 'The need for personalised medicine for rheumatoid arthritis ' (2011 ) 70 Ann. Rheum. Dis. : 4 -7.

    • Search Google Scholar
  • Cronstein, B. N.: Pharmacogenetics in the rheumatic diseases, from prêt-à-porter to haute couture. Nat. Clin. Pract. Rheumatol., 2006, 2, 2–3.

    Cronstein B. N. , 'Pharmacogenetics in the rheumatic diseases, from prêt-à-porter to haute couture ' (2006 ) 2 Nat. Clin. Pract. Rheumatol. : 2 -3.

    • Search Google Scholar
  • Szekanecz, Z., Szanto, S., Szabo, Z., et al.: Biologics – beyond the joints. Autoimmun. Rev., 2010, 9, 820–824.

    Szabo Z. , 'Biologics – beyond the joints ' (2010 ) 9 Autoimmun. Rev. : 820 -824.

  • Szekanecz, Z., Váncsa, A., Soós, B., et al.: Changes in biologic therapies – on the road of personalized medicine. [Biológiai terápia váltások rheumatoid arthritisben – a személyre szabott orvoslás útján.] Immunol. Szemle, 2012, 4, 29–39. [Hungarian]

    Soós B. , 'Changes in biologic therapies – on the road of personalized medicine. [Biológiai terápia váltások rheumatoid arthritisben – a személyre szabott orvoslás útján.] ' (2012 ) 4 Immunol. Szemle : 29 -39.

    • Search Google Scholar
  • Tamási, L., Szekanecz, Z.: Biological therapy of arthritis and systemic autoimmune diseases. [A biológiai terápia lehetőségei az arthritisek és a szisztémás autoimmun kórképek kezelésében.] Orv. Hetil., 2007, 148 (Suppl. 1), 63–70. [Hungarian]

    Szekanecz Z. , 'Biological therapy of arthritis and systemic autoimmune diseases. [A biológiai terápia lehetőségei az arthritisek és a szisztémás autoimmun kórképek kezelésében.] ' (2007 ) 148 Orv. Hetil. : 63 -70.

    • Search Google Scholar
  • Alamanos, Y., Drosos, A. A.: Epidemiology of adult rheumatoid arthritis. Autoimmun. Rev., 2005, 4, 130–136.

    Drosos A. A. , 'Epidemiology of adult rheumatoid arthritis ' (2005 ) 4 Autoimmun. Rev. : 130 -136.

    • Search Google Scholar
  • Smolen, J. S., Landewe, R., Breedveld, F. C., et al.: EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann. Rheum. Dis., 2010, 69, 964–975.

    Breedveld F. C. , 'EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs ' (2010 ) 69 Ann. Rheum. Dis. : 964 -975.

    • Search Google Scholar
  • Smolen, J. S., Aletaha, D., Bijlsma, J. W., et al.: Treating rheumatoid arthritis to target: recommendations of an international task force. Ann. Rheum. Dis., 2010, 69, 631–637.

    Bijlsma J. W. , 'Treating rheumatoid arthritis to target: recommendations of an international task force ' (2010 ) 69 Ann. Rheum. Dis. : 631 -637.

    • Search Google Scholar
  • Aletaha, D., Neogi, T., Silman, A. J., et al.: 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann. Rheum. Dis., 2010, 69, 1580–1588.

    Silman A. J. , '2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative ' (2010 ) 69 Ann. Rheum. Dis. : 1580 -1588.

    • Search Google Scholar
  • Felson, D. T., Smolen, J. S., Wells, G., et al.: American College of Rheumatology/European League against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Ann. Rheum. Dis., 2011, 70, 404–413.

    Wells G. , 'American College of Rheumatology/European League against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials ' (2011 ) 70 Ann. Rheum. Dis. : 404 -413.

    • Search Google Scholar
  • Klareskog, L., Widhe, M., Hermansson, M., et al.: Antibodies to citrullinated proteins in arthritis: pathology and promise. Curr. Opin. Rheumatol., 2008, 20, 300–305.

    Hermansson M. , 'Antibodies to citrullinated proteins in arthritis: pathology and promise ' (2008 ) 20 Curr. Opin. Rheumatol. : 300 -305.

    • Search Google Scholar
  • Soós, L., Lakos, G., Kapitány, A., et al.: Pathogenetic, diagnostic and prognostic significance of anti-citrullinated protein antibodies (ACPA). [A citrullinált fehérje elleni antitestek (ACPA) pathogenetikai, diagnosztikus és prognosztikai jelentősége.] Immunol. Szemle, 2009, 1–2, 4–12. [Hungarian]

    Kapitány A. , 'Pathogenetic, diagnostic and prognostic significance of anti-citrullinated protein antibodies (ACPA). [A citrullinált fehérje elleni antitestek (ACPA) pathogenetikai, diagnosztikus és prognosztikai jelentősége.] ' (2009 ) 1–2 Immunol. Szemle : 4 -12.

    • Search Google Scholar
  • Szodoray, P., Szabó, Z., Kapitány, A., et al.: Anti-citrullinated protein/peptide autoantibodies in association with genetic and environmental factors as indicators of disease outcome in rheumatoid arthritis. Autoimmun. Rev., 2010, 9, 140–143.

    Kapitány A. , 'Anti-citrullinated protein/peptide autoantibodies in association with genetic and environmental factors as indicators of disease outcome in rheumatoid arthritis ' (2010 ) 9 Autoimmun. Rev. : 140 -143.

    • Search Google Scholar
  • Daha, N. A., Toes, R. E.: Rheumatoid arthritis: Are ACPA-positive and ACPA-negative RA the same disease?. Nat. Rev. Rheumatol., 2011, 7, 202–203.

    Toes R. E. , 'Rheumatoid arthritis: Are ACPA-positive and ACPA-negative RA the same disease? ' (2011 ) 7 Nat. Rev. Rheumatol. : 202 -203.

    • Search Google Scholar
  • Van Vollenhoven, R. F.: Switching between anti-tumour necrosis factors: trying to get a handle on a complex issue. Ann. Rheum. Dis., 2007, 66, 849–851.

    Vollenhoven R. F. , 'Switching between anti-tumour necrosis factors: trying to get a handle on a complex issue ' (2007 ) 66 Ann. Rheum. Dis. : 849 -851.

    • Search Google Scholar
  • Gomez-Reino, J. J., Carmona, L.: Switching TNF antagonists in patients with chronic arthritis: an observational study of 488 patients over a four-year period. Arthritis Res. Ther., 2006, 8, R29.

    Carmona L. , 'Switching TNF antagonists in patients with chronic arthritis: an observational study of 488 patients over a four-year period ' (2006 ) 8 Arthritis Res. Ther. : R29 -.

    • Search Google Scholar
  • Rubbert-Roth, A., Finckh, A.: Treatment options in patients with rheumatoid arthritis failing initial TNF inhibitor therapy: a critical review. Arthritis Res. Ther., 2009, 11 (Suppl 1), S1.

    Finckh A. , 'Treatment options in patients with rheumatoid arthritis failing initial TNF inhibitor therapy: a critical review ' (2009 ) 11 Arthritis Res. Ther. : S1 -.

    • Search Google Scholar
  • Simard, J. F., Arkema, E. V., Sundstrom, A., et al.: Ten years with biologics: to whom do data on effectiveness and safety apply?. Rheumatology (Oxford), 2011, 50, 204–213.

    Sundstrom A. , 'Ten years with biologics: to whom do data on effectiveness and safety apply? ' (2011 ) 50 Rheumatology (Oxford) : 204 -213.

    • Search Google Scholar
  • Vital, E. M., Dass, S., Rawstron, A. C., et al.: Management of nonresponse to rituximab in rheumatoid arthritis: predictors and outcome of re-treatment. Arthritis Rheum., 2010, 62, 1273–1279.

    Rawstron A. C. , 'Management of nonresponse to rituximab in rheumatoid arthritis: predictors and outcome of re-treatment ' (2010 ) 62 Arthritis Rheum. : 1273 -1279.

    • Search Google Scholar
  • Emery, P., Dorner, T.: Optimising treatment in rheumatoid arthritis: a review of potential biological markers of response. Ann. Rheum. Dis., 2011, 70, 2063–2070.

    Dorner T. , 'Optimising treatment in rheumatoid arthritis: a review of potential biological markers of response ' (2011 ) 70 Ann. Rheum. Dis. : 2063 -2070.

    • Search Google Scholar
  • Hyrich, K. L., Watson, K. D., Silman, A. J., et al.: Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Rheumatology (Oxford), 2006, 45, 1558–1565.

    Silman A. J. , 'Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register ' (2006 ) 45 Rheumatology (Oxford) : 1558 -1565.

    • Search Google Scholar
  • Kristensen, L. E., Kapetanovic, M. C., Gulfe, A., et al.: Predictors of response to anti-TNF therapy according to ACR and EULAR criteria in patients with established RA: results from the South Swedish Arthritis Treatment Group Register. Rheumatology (Oxford), 2008, 47, 495–499.

    Gulfe A. , 'Predictors of response to anti-TNF therapy according to ACR and EULAR criteria in patients with established RA: results from the South Swedish Arthritis Treatment Group Register ' (2008 ) 47 Rheumatology (Oxford) : 495 -499.

    • Search Google Scholar
  • Sellam, J., Hendel-Chavez, H., Rouanet, S., et al.: B cell activation biomarkers as predictive factors for the response to rituximab in rheumatoid arthritis: a six-month, national, multicenter, open-label study. Arthritis Rheum., 2011, 63, 933–938.

    Rouanet S. , 'B cell activation biomarkers as predictive factors for the response to rituximab in rheumatoid arthritis: a six-month, national, multicenter, open-label study ' (2011 ) 63 Arthritis Rheum. : 933 -938.

    • Search Google Scholar
  • Sellam, J., Rouanet, S., Hendel-Chavez, H., et al.: Blood memory B cells are disturbed and predict the response to rituximab in patients with rheumatoid arthritis. Arthritis Rheum., 2011, 63, 3692–3701.

    Hendel-Chavez H. , 'Blood memory B cells are disturbed and predict the response to rituximab in patients with rheumatoid arthritis ' (2011 ) 63 Arthritis Rheum. : 3692 -3701.

    • Search Google Scholar
  • Ruyssen-Witrand, A., Rouanet, S., Combe, B., et al.: Fcgamma receptor type IIIA polymorphism influences treatment outcomes in patients with rheumatoid arthritis treated with rituximab. Ann. Rheum. Dis., 2012, 71, 875–877.

    Combe B. , 'Fcgamma receptor type IIIA polymorphism influences treatment outcomes in patients with rheumatoid arthritis treated with rituximab ' (2012 ) 71 Ann. Rheum. Dis. : 875 -877.

    • Search Google Scholar
  • Quartuccio, L., Fabris, M., Salvin, S., et al.: Rheumatoid factor positivity rather than anti-CCP positivity, a lower disability and a lower number of anti-TNF agents failed are associated with response to rituximab in rheumatoid arthritis. Rheumatology (Oxford), 2009, 48, 1557–1559.

    Salvin S. , 'Rheumatoid factor positivity rather than anti-CCP positivity, a lower disability and a lower number of anti-TNF agents failed are associated with response to rituximab in rheumatoid arthritis ' (2009 ) 48 Rheumatology (Oxford) : 1557 -1559.

    • Search Google Scholar
  • Garcês, S., Demengeot, J., Benito-Garcia, E.: The immunogenicity of anti-TNF therapy in immune-mediated inflammatory diseases: a systematic review of the literature with a meta-analysis. Ann. Rheum. Dis., 2012 Dec 6. [Epub ahead of print]

  • Rendas-Baum, R., Wallenstein, G. V., Koncz, T., et al.: Evaluating the efficacy of sequential biologic therapies for rheumatoid arthritis patients with an inadequate response to tumor necrosis factor-alpha inhibitors. Arthritis Res. Ther., 2011, 13, R25.

    Koncz T. , 'Evaluating the efficacy of sequential biologic therapies for rheumatoid arthritis patients with an inadequate response to tumor necrosis factor-alpha inhibitors ' (2011 ) 13 Arthritis Res. Ther. : R25 -.

    • Search Google Scholar
  • Solau-Gervais, E., Laxenaire, N., Cortet, B., et al.: Lack of efficacy of a third tumour necrosis factor alpha antagonist after failure of a soluble receptor and a monoclonal antibody. Rheumatology (Oxford), 2006, 45, 1121–1124.

    Cortet B. , 'Lack of efficacy of a third tumour necrosis factor alpha antagonist after failure of a soluble receptor and a monoclonal antibody ' (2006 ) 45 Rheumatology (Oxford) : 1121 -1124.

    • Search Google Scholar
  • Keystone, E., Burmester, G. R., Furie, R., et al.: Improvement in patient-reported outcomes in a rituximab trial in patients with severe rheumatoid arthritis refractory to anti-tumor necrosis factor therapy. Arthritis Rheum., 2008, 59, 785–793.

    Furie R. , 'Improvement in patient-reported outcomes in a rituximab trial in patients with severe rheumatoid arthritis refractory to anti-tumor necrosis factor therapy ' (2008 ) 59 Arthritis Rheum. : 785 -793.

    • Search Google Scholar
  • Paccou, J., Solau-Gervais, E., Houvenagel, E., et al.: Efficacy in current practice of switching between anti-tumour necrosis factor-alpha agents in spondyloarthropathies. Rheumatology (Oxford), 2011, 50, 714–720.

    Houvenagel E. , 'Efficacy in current practice of switching between anti-tumour necrosis factor-alpha agents in spondyloarthropathies ' (2011 ) 50 Rheumatology (Oxford) : 714 -720.

    • Search Google Scholar
  • Finckh, A., Ciurea, A., Brulhart, L., et al.: B cell depletion may be more effective than switching to an alternative anti-tumor necrosis factor agent in rheumatoid arthritis patients with inadequate response to anti-tumor necrosis factor agents. Arthritis Rheum., 2007, 56, 1417–1423.

    Brulhart L. , 'B cell depletion may be more effective than switching to an alternative anti-tumor necrosis factor agent in rheumatoid arthritis patients with inadequate response to anti-tumor necrosis factor agents ' (2007 ) 56 Arthritis Rheum. : 1417 -1423.

    • Search Google Scholar
  • Chatzidionysiou, K., Lie, E., Nasonov, E., et al.: Highest clinical effectiveness of rituximab in autoantibody-positive patients with rheumatoid arthritis and in those for whom no more than one previous TNF antagonist has failed: pooled data from 10 European registries. Ann. Rheum. Dis., 2011, 70, 1575–1580.

    Nasonov E. , 'Highest clinical effectiveness of rituximab in autoantibody-positive patients with rheumatoid arthritis and in those for whom no more than one previous TNF antagonist has failed: pooled data from 10 European registries ' (2011 ) 70 Ann. Rheum. Dis. : 1575 -1580.

    • Search Google Scholar
  • Klareskog, L., Padyukov, L., Ronnelid, J., et al.: Genes, environment and immunity in the development of rheumatoid arthritis. Curr. Opin. Immunol., 2006, 18, 650–655.

    Ronnelid J. , 'Genes, environment and immunity in the development of rheumatoid arthritis ' (2006 ) 18 Curr. Opin. Immunol. : 650 -655.

    • Search Google Scholar
  • Pedersen, M., Jacobsen, S., Garred, P., et al.: Strong combined gene-environment effects in anti-cyclic citrullinated peptide-positive rheumatoid arthritis: a nationwide case-control study in Denmark. Arthritis Rheum., 2007, 56, 1446–1453.

    Garred P. , 'Strong combined gene-environment effects in anti-cyclic citrullinated peptide-positive rheumatoid arthritis: a nationwide case-control study in Denmark ' (2007 ) 56 Arthritis Rheum. : 1446 -1453.

    • Search Google Scholar
  • Padyukov, L., Silva, C., Stolt, P., et al.: A gene-environment interaction between smoking and shared epitope genes in HLA-DR provides a high risk of seropositive rheumatoid arthritis. Arthritis Rheum., 2004, 50, 3085–3092.

    Stolt P. , 'A gene-environment interaction between smoking and shared epitope genes in HLA-DR provides a high risk of seropositive rheumatoid arthritis ' (2004 ) 50 Arthritis Rheum. : 3085 -3092.

    • Search Google Scholar
  • Besenyei, T., Gyetvai, A., Szabo, Z., et al.: Associations of HLA-shared epitope, anti-citrullinated peptide antibodies and lifestyle-related factors in Hungarian patients with rheumatoid arthritis: data from the first Central-Eastern European cohort. Joint Bone Spine, 2011, 78, 652–653.

    Szabo Z. , 'Associations of HLA-shared epitope, anti-citrullinated peptide antibodies and lifestyle-related factors in Hungarian patients with rheumatoid arthritis: data from the first Central-Eastern European cohort ' (2011 ) 78 Joint Bone Spine : 652 -653.

    • Search Google Scholar
  • Mattey, D. L., Brownfield, A., Dawes, P. T.: Relationship between pack-year history of smoking and response to tumor necrosis factor antagonists in patients with rheumatoid arthritis. J. Rheumatol., 2009, 36, 1180–1187.

    Dawes P. T. , 'Relationship between pack-year history of smoking and response to tumor necrosis factor antagonists in patients with rheumatoid arthritis ' (2009 ) 36 J. Rheumatol. : 1180 -1187.

    • Search Google Scholar
  • Hetland, M. L., Christensen, I. J., Tarp, U., et al.: Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry. Arthritis Rheum., 2010, 62, 22–32.

    Tarp U. , 'Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry ' (2010 ) 62 Arthritis Rheum. : 22 -32.

    • Search Google Scholar
  • Mancarella, L., Bobbio-Pallavicini, F., Ceccarelli, F., et al.: Good clinical response, remission, and predictors of remission in rheumatoid arthritis patients treated with tumor necrosis factor-alpha blockers: the GISEA study. J. Rheumatol., 2007, 34, 1670–1673.

    Ceccarelli F. , 'Good clinical response, remission, and predictors of remission in rheumatoid arthritis patients treated with tumor necrosis factor-alpha blockers: the GISEA study ' (2007 ) 34 J. Rheumatol. : 1670 -1673.

    • Search Google Scholar
  • Shoenfeld, Y., Gerli, R., Doria, A., et al.: Accelerated atherosclerosis in autoimmune rheumatic diseases. Circulation, 2005, 112, 3337–3347.

    Doria A. , 'Accelerated atherosclerosis in autoimmune rheumatic diseases ' (2005 ) 112 Circulation : 3337 -3347.

    • Search Google Scholar
  • Szekanecz, Z., Soltész, P., Kerekes, G., et al.: Accelerated atherosclerosis and neuropathy in autoimmune rheumatologic disorders. [Akcelerált atherosclerosis és vasculopathiák autoimmun-reumatológiai betegségekben.] Immunol. Szemle, 2010, 2 (2), 4–14. [Hungarian]

    Kerekes G. , 'Accelerated atherosclerosis and neuropathy in autoimmune rheumatologic disorders. [Akcelerált atherosclerosis és vasculopathiák autoimmun-reumatológiai betegségekben.] ' (2010 ) 2 Immunol. Szemle : 4 -14.

    • Search Google Scholar
  • Szekanecz, Z., Szekanecz, E., Bakó, G., et al.: Malignancies in autoimmune rheumatic diseases – a mini-review. Gerontology, 2011, 57, 3–10.

    Bakó G. , 'Malignancies in autoimmune rheumatic diseases – a mini-review ' (2011 ) 57 Gerontology : 3 -10.

    • Search Google Scholar
  • Gravallese, E. M.: Bone destruction in arthritis. Ann. Rheum. Dis., 2002, 61 (Suppl. 2:ii), 84–86.

    Gravallese E. M. , 'Bone destruction in arthritis ' (2002 ) 61 Ann. Rheum. Dis. : 84 -86.

  • Szekanecz, Z., Elek, I., Bettembuk, P., et al.: Secondary osteoporosis in rheumatoid arthritis. [Secundaer osteoporosis rheumatoid arthritisben.] Magyar Belorv. Arch., 1998, 267–271. [Hungarian]

    Bettembuk P. , 'Secondary osteoporosis in rheumatoid arthritis. [Secundaer osteoporosis rheumatoid arthritisben.] ' (1998 ) Magyar Belorv. Arch. : 267 -271.

    • Search Google Scholar
  • Szekanecz, Z., Kerekes, G., Nurmohamed, M.: Systemic consequences of inflammation. In: EULAR Textbook on Rheumatic Diseases. Ed. Bijlsma, JWJ., 2012, 390–420.

    Nurmohamed M. , '', in EULAR Textbook on Rheumatic Diseases , (2012 ) -.

  • Kojima, M., Kojima, T., Suzuki, S., et al.: Depression, inflammation, and pain in patients with rheumatoid arthritis. Arthritis Rheum., 2009, 61, 1018–1024.

    Suzuki S. , 'Depression, inflammation, and pain in patients with rheumatoid arthritis ' (2009 ) 61 Arthritis Rheum. : 1018 -1024.

    • Search Google Scholar
  • Peters, M. J., Symmons, D. P., McCarey, D., et al.: EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Ann. Rheum. Dis., 2010, 69, 325–331.

    McCarey D. , 'EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis ' (2010 ) 69 Ann. Rheum. Dis. : 325 -331.

    • Search Google Scholar
  • Szekanecz, Z., Kerekes, G., Soltész, P.: Vascular effects of biologic agents in RA and spondyloarthropathies. Nat. Rev. Rheumatol., 2009, 5, 677–684.

    Soltész P. , 'Vascular effects of biologic agents in RA and spondyloarthropathies ' (2009 ) 5 Nat. Rev. Rheumatol. : 677 -684.

    • Search Google Scholar
  • Barnabe, C., Hanley, D. A.: Effect of tumor necrosis factor alpha inhibition on bone density and turnover markers in patients with rheumatoid arthritis and spondyloarthropathy. Semin. Arthritis Rheum., 2009, 39, 116–122.

    Hanley D. A. , 'Effect of tumor necrosis factor alpha inhibition on bone density and turnover markers in patients with rheumatoid arthritis and spondyloarthropathy ' (2009 ) 39 Semin. Arthritis Rheum. : 116 -122.

    • Search Google Scholar
  • Szekanecz, Z.: Effect of targeted therapies on bone. [A célzott terápiák csonthatásai.] LAM KID, 2012, 2, 24–31. [Hungarian]

    Szekanecz Z. , 'Effect of targeted therapies on bone. [A célzott terápiák csonthatásai.] ' (2012 ) 2 LAM KID : 24 -31.

    • Search Google Scholar
  • Askling, J., van Vollenhoven, R. F., Granath, F., et al.: Cancer risk in patients with rheumatoid arthritis treated with anti-tumor necrosis factor alpha therapies: does the risk change with the time since start of treatment?. Arthritis Rheum., 2009, 60, 3180–3189.

    Granath F. , 'Cancer risk in patients with rheumatoid arthritis treated with anti-tumor necrosis factor alpha therapies: does the risk change with the time since start of treatment? ' (2009 ) 60 Arthritis Rheum. : 3180 -3189.

    • Search Google Scholar
  • Wolfe, F., Michaud, K.: The effect of methotrexate and anti-tumor necrosis factor therapy on the risk of lymphoma in rheumatoid arthritis in 19,562 patients during 89,710 person-years of observation. Arthritis Rheum., 2007, 56, 1433–1439.

    Michaud K. , 'The effect of methotrexate and anti-tumor necrosis factor therapy on the risk of lymphoma in rheumatoid arthritis in 19,562 patients during 89,710 person-years of observation ' (2007 ) 56 Arthritis Rheum. : 1433 -1439.

    • Search Google Scholar
  • Dixon, W. G., Watson, K. D., Lunt, M., et al.: Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti-tumor necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum., 2007, 56, 2905–2912.

    Lunt M. , 'Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti-tumor necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register ' (2007 ) 56 Arthritis Rheum. : 2905 -2912.

    • Search Google Scholar
  • Jacobsson, L. T., Turesson, C., Nilsson, J. A., et al.: Treatment with TNF blockers and mortality risk in patients with rheumatoid arthritis. Ann. Rheum. Dis., 2007, 66, 670–675.

    Nilsson J. A. , 'Treatment with TNF blockers and mortality risk in patients with rheumatoid arthritis ' (2007 ) 66 Ann. Rheum. Dis. : 670 -675.

    • Search Google Scholar
  • Greenberg, J. D., Kremer, J. M., Curtis, J. R., et al.: Tumour necrosis factor antagonist use and associated risk reduction of cardiovascular events among patients with rheumatoid arthritis. Ann. Rheum. Dis., 2011, 70, 576–582.

    Curtis J. R. , 'Tumour necrosis factor antagonist use and associated risk reduction of cardiovascular events among patients with rheumatoid arthritis ' (2011 ) 70 Ann. Rheum. Dis. : 576 -582.

    • Search Google Scholar
  • Wolfe, F., Michaud, K.: Heart failure in rheumatoid arthritis: rates, predictors, and the effect of anti-tumor necrosis factor therapy. Am. J. Med., 2004, 116, 305–311.

    Michaud K. , 'Heart failure in rheumatoid arthritis: rates, predictors, and the effect of anti-tumor necrosis factor therapy ' (2004 ) 116 Am. J. Med. : 305 -311.

    • Search Google Scholar
  • Choy, E., Sattar, N.: Interpreting lipid levels in the context of high-grade inflammatory states with a focus on rheumatoid arthritis: a challenge to conventional cardiovascular risk actions. Ann. Rheum. Dis., 2009, 68, 460–469.

    Sattar N. , 'Interpreting lipid levels in the context of high-grade inflammatory states with a focus on rheumatoid arthritis: a challenge to conventional cardiovascular risk actions ' (2009 ) 68 Ann. Rheum. Dis. : 460 -469.

    • Search Google Scholar
  • Popa, C., van den Hoogen, F. H., Radstake, T. R., et al.: Modulation of lipoprotein plasma concentrations during long-term anti-TNF therapy in patients with active rheumatoid arthritis. Ann. Rheum. Dis., 2007, 66, 1503–1507.

    Radstake T. R. , 'Modulation of lipoprotein plasma concentrations during long-term anti-TNF therapy in patients with active rheumatoid arthritis ' (2007 ) 66 Ann. Rheum. Dis. : 1503 -1507.

    • Search Google Scholar
  • Kawashiri, S. Y., Kawakami, A., Yamasaki, S., et al.: Effects of the anti-interleukin-6 receptor antibody, tocilizumab, on serum lipid levels in patients with rheumatoid arthritis. Rheumatol. Int., 2010, 31, 451–456.

    Yamasaki S. , 'Effects of the anti-interleukin-6 receptor antibody, tocilizumab, on serum lipid levels in patients with rheumatoid arthritis ' (2010 ) 31 Rheumatol. Int. : 451 -456.

    • Search Google Scholar
  • Myasoedova, E., Crowson, C. S., Kremers, H. M., et al.: Total cholesterol and LDL levels decrease before rheumatoid arthritis. Ann. Rheum. Dis., 2010, 69, 1310–1314.

    Kremers H. M. , 'Total cholesterol and LDL levels decrease before rheumatoid arthritis ' (2010 ) 69 Ann. Rheum. Dis. : 1310 -1314.

    • Search Google Scholar
  • Myasoedova, E., Crowson, C. S., Kremers, H. M., et al.: Lipid paradox in rheumatoid arthritis: the impact of serum lipid measures and systemic inflammation on the risk of cardiovascular disease. Ann. Rheum. Dis., 2011, 70, 482–487.

    Kremers H. M. , 'Lipid paradox in rheumatoid arthritis: the impact of serum lipid measures and systemic inflammation on the risk of cardiovascular disease ' (2011 ) 70 Ann. Rheum. Dis. : 482 -487.

    • Search Google Scholar
  • Ridker, P. M., Cook, N.: Clinical usefulness of very high and very low levels of C-reactive protein across the full range of Framingham Risk Scores. Circulation, 2004, 109 (16), 1955–1959.

    Cook N. , 'Clinical usefulness of very high and very low levels of C-reactive protein across the full range of Framingham Risk Scores ' (2004 ) 109 Circulation : 1955 -1959.

    • Search Google Scholar
  • Suissa, S., Bernatsky, S., Hudson, M.: Antirheumatic drug use and the risk of acute myocardial infarction. Arthritis Rheum., 2006, 55, 531–536.

    Hudson M. , 'Antirheumatic drug use and the risk of acute myocardial infarction ' (2006 ) 55 Arthritis Rheum. : 531 -536.

    • Search Google Scholar
  • Singh, G., Wu, O., Langhorne, P., et al.: Risk of acute myocardial infarction with nonselective non-steroidal anti-inflammatory drugs: a meta-analysis. Arthritis Res. Ther., 2006, 8, R153.

    Langhorne P. , 'Risk of acute myocardial infarction with nonselective non-steroidal anti-inflammatory drugs: a meta-analysis ' (2006 ) 8 Arthritis Res. Ther. : R153 -.

    • Search Google Scholar
  • Pijpe, J., van Imhoff, G. W., Spijkervet, F. K., et al.: Rituximab treatment in patients with primary Sjogren’s syndrome: an open-label phase II study. Arthritis Rheum., 2005, 52, 2740–2750.

    Spijkervet F. K. , 'Rituximab treatment in patients with primary Sjogren’s syndrome: an open-label phase II study ' (2005 ) 52 Arthritis Rheum. : 2740 -2750.

    • Search Google Scholar
  • Pierreisnard, A., Issa, N., Barnetche, T., et al.: Meta-analysis of clinical and radiological efficacy of biologics in rheumatoid arthritis patients naive or inadequately responsive to methotrexate. Joint Bone Spine, 2012 Nov 6. pii: S1297-319X(12)00228-X. doi: 10.1016/j.jbspin.2012.09.023 . [Epub ahead of print]

  • Nemeth, E., Rivera, S., Gabayan, V., et al.: IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J. Clin. Invest., 2004, 113, 1271–1276.

    Gabayan V. , 'IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin ' (2004 ) 113 J. Clin. Invest. : 1271 -1276.

    • Search Google Scholar
  • Genovese, M. C., McKay, J. D., Nasonov, E. L., et al.: Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study. Arthritis Rheum., 2008, 58, 2968–2980.

    Nasonov E. L. , 'Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study ' (2008 ) 58 Arthritis Rheum. : 2968 -2980.

    • Search Google Scholar
  • Doyle, M. K., Rahman, M. U., Han, C., et al.: Treatment with infliximab plus methotrexate improves anemia in patients with rheumatoid arthritis independent of improvement in other clinical outcome measures – a pooled analysis from three large, multicenter, double-blind, randomized clinical trials. Semin. Arthritis Rheum., 2009, 39, 123–131.

    Han C. , 'Treatment with infliximab plus methotrexate improves anemia in patients with rheumatoid arthritis independent of improvement in other clinical outcome measures – a pooled analysis from three large, multicenter, double-blind, randomized clinical trials ' (2009 ) 39 Semin. Arthritis Rheum. : 123 -131.

    • Search Google Scholar
  • Perfetto, F., Moggi-Pignone, A., Livi, R., et al.: Systemic amyloidosis: a challenge for the rheumatologist. Nat. Rev. Rheumatol., 2010, 6, 417–429.

    Livi R. , 'Systemic amyloidosis: a challenge for the rheumatologist ' (2010 ) 6 Nat. Rev. Rheumatol. : 417 -429.

    • Search Google Scholar
  • Perry, M. E., Stirling, A., Hunter, J. A.: Effect of etanercept on serum amyloid A protein (SAA) levels in patients with AA amyloidosis complicating inflammatory arthritis. Clin. Rheumatol., 2008, 27, 923–925.

    Hunter J. A. , 'Effect of etanercept on serum amyloid A protein (SAA) levels in patients with AA amyloidosis complicating inflammatory arthritis ' (2008 ) 27 Clin. Rheumatol. : 923 -925.

    • Search Google Scholar
  • Nishida, S., Hagihara, K., Shima, Y., et al.: Rapid improvement of AA amyloidosis with humanised anti-interleukin 6 receptor antibody treatment. Ann. Rheum. Dis., 2009, 68, 1235–1236.

    Shima Y. , 'Rapid improvement of AA amyloidosis with humanised anti-interleukin 6 receptor antibody treatment ' (2009 ) 68 Ann. Rheum. Dis. : 1235 -1236.

    • Search Google Scholar
  • Chrousos, G. P.: The hypothalamic-pituitary-adrenal axis and immune-mediated inflammation. N. Engl. J. Med., 1995, 332, 1351–1362.

    Chrousos G. P. , 'The hypothalamic-pituitary-adrenal axis and immune-mediated inflammation ' (1995 ) 332 N. Engl. J. Med. : 1351 -1362.

    • Search Google Scholar
  • Chauffier, K., Salliot, C., Berenbaum, F., et al.: Effect of biotherapies on fatigue in rheumatoid arthritis: a systematic review of the literature and meta-analysis. Rheumatology (Oxford), 2011, 51, 60–88.

    Berenbaum F. , 'Effect of biotherapies on fatigue in rheumatoid arthritis: a systematic review of the literature and meta-analysis ' (2011 ) 51 Rheumatology (Oxford) : 60 -88.

    • Search Google Scholar
  • Strand, V., Singh, J. A.: Improved health-related quality of life with effective disease-modifying antirheumatic drugs: evidence from randomized controlled trials. Am. J. Manag. Care, 2008, 14, 234–254.

    Singh J. A. , 'Improved health-related quality of life with effective disease-modifying antirheumatic drugs: evidence from randomized controlled trials ' (2008 ) 14 Am. J. Manag. Care : 234 -254.

    • Search Google Scholar
  • Szekanecz, Z., Koch, A. E.: Update on synovitis. Curr. Rheumatol. Rep., 2001, 3, 53–63.

    Koch A. E. , 'Update on synovitis ' (2001 ) 3 Curr. Rheumatol. Rep. : 53 -63.

  • Szekanecz, Z. (ed.): Rheumatology. [Reumatológia.] SpringMed Kiadó, Budapest, 2011. [Hungarian]

    '', in Rheumatology. [Reumatológia.] , (2011 ) -.

  • Panayi, G. S.: Targeting of cells involved in the pathogenesis of rheumatoid arthritis. Rheumatology (Oxford), 1999, 38 (Suppl. 2), 8–10.

    Panayi G. S. , 'Targeting of cells involved in the pathogenesis of rheumatoid arthritis ' (1999 ) 38 Rheumatology (Oxford) : 8 -10.

    • Search Google Scholar
  • Váncsa, A., Szabó, Z., Szamosi, S., et al.: Long-term experience with rituximab therapy in patients with rheumatoid arthritis. [Rituximabterápiával szerzett hosszú távú tapasztalataink rheumatoid arthritises beteganyagunkban.] Immunol. Szemle, 2010, 2, 21–26. [Hungarian]

    Szamosi S. , 'Long-term experience with rituximab therapy in patients with rheumatoid arthritis. [Rituximabterápiával szerzett hosszú távú tapasztalataink rheumatoid arthritises beteganyagunkban.] ' (2010 ) 2 Immunol. Szemle : 21 -26.

    • Search Google Scholar
  • Váncsa, A., Szabó, Z., Szamosi, S., et al.: Long-term effects of rituximab on B-cell counts and autoantibody production in rheumatoid arthritis: use of high-sensitivity flow-cytometry for more sensitive assessment of B-cell depletion. Ann. Rheum. Dis., 2012, 71, A1. doi:10.1136/annrheumdis-2011-201230.1

    Szamosi S. , 'Long-term effects of rituximab on B-cell counts and autoantibody production in rheumatoid arthritis: use of high-sensitivity flow-cytometry for more sensitive assessment of B-cell depletion ' (2012 ) 71 Ann. Rheum. Dis. : A1 -.

    • Search Google Scholar
  • Dass, S., Rawstron, A. C., Vital, E. M., et al.: Highly sensitive B cell analysis predicts response to rituximab therapy in rheumatoid arthritis. Arthritis Rheum., 2008, 58, 2993–2999.

    Vital E. M. , 'Highly sensitive B cell analysis predicts response to rituximab therapy in rheumatoid arthritis ' (2008 ) 58 Arthritis Rheum. : 2993 -2999.

    • Search Google Scholar
  • Boumans, M. J., Tak, P. P.: Rituximab treatment in rheumatoid arthritis: how does it work?. Arthritis Res. Ther., 2009, 11, 134.

    Tak P. P. , 'Rituximab treatment in rheumatoid arthritis: how does it work? ' (2009 ) 11 Arthritis Res. Ther. : 134 -.

    • Search Google Scholar
  • Roll, P., Palanichamy, A., Kneitz, C., et al.: Regeneration of B cell subsets after transient B cell depletion using anti-CD20 antibodies in rheumatoid arthritis. Arthritis Rheum., 2006, 54, 2377–2386.

    Kneitz C. , 'Regeneration of B cell subsets after transient B cell depletion using anti-CD20 antibodies in rheumatoid arthritis ' (2006 ) 54 Arthritis Rheum. : 2377 -2386.

    • Search Google Scholar
  • Atzeni, F., Doria, A., Maurizio, T., et al.: What is the role of rituximab in the treatment of rheumatoid arthritis?. Autoimmun. Rev., 2007, 6, 553–558.

    Maurizio T. , 'What is the role of rituximab in the treatment of rheumatoid arthritis? ' (2007 ) 6 Autoimmun. Rev. : 553 -558.

    • Search Google Scholar
  • Thurlings, R. M., Teng, O., Vos, K., et al.: Clinical response, pharmacokinetics, development of human anti-chimaeric antibodies, and synovial tissue response to rituximab treatment in patients with rheumatoid arthritis. Ann. Rheum. Dis., 2009, 69, 409–412.

    Vos K. , 'Clinical response, pharmacokinetics, development of human anti-chimaeric antibodies, and synovial tissue response to rituximab treatment in patients with rheumatoid arthritis ' (2009 ) 69 Ann. Rheum. Dis. : 409 -412.

    • Search Google Scholar
  • Wijbrandts, C. A., Dijkgraaf, M. G., Kraan, M. C., et al.: The clinical response to infliximab in rheumatoid arthritis is in part dependent on pretreatment tumour necrosis factor alpha expression in the synovium. Ann. Rheum. Dis., 2008, 67, 1139–1144.

    Kraan M. C. , 'The clinical response to infliximab in rheumatoid arthritis is in part dependent on pretreatment tumour necrosis factor alpha expression in the synovium ' (2008 ) 67 Ann. Rheum. Dis. : 1139 -1144.

    • Search Google Scholar
  • Thurlings, R. M., Vos, K., Wijbrandts, C. A., et al.: Synovial tissue response to rituximab: mechanism of action and identification of biomarkers of response. Ann. Rheum. Dis., 2008, 67, 917–925.

    Wijbrandts C. A. , 'Synovial tissue response to rituximab: mechanism of action and identification of biomarkers of response ' (2008 ) 67 Ann. Rheum. Dis. : 917 -925.

    • Search Google Scholar
  • Klimiuk, P. A., Sierakowski, S., Latosiewicz, R., et al.: Histological patterns of synovitis and serum chemokines in patients with rheumatoid arthritis. J. Rheumatol., 2005, 32, 1666–1672.

    Latosiewicz R. , 'Histological patterns of synovitis and serum chemokines in patients with rheumatoid arthritis ' (2005 ) 32 J. Rheumatol. : 1666 -1672.

    • Search Google Scholar
  • Thurlings, R. M., Wijbrandts, C. A., Mebius, R. E., et al.: Synovial lymphoid neogenesis does not define a specific clinical rheumatoid arthritis phenotype. Arthritis Rheum., 2008, 58, 1582–1589.

    Mebius R. E. , 'Synovial lymphoid neogenesis does not define a specific clinical rheumatoid arthritis phenotype ' (2008 ) 58 Arthritis Rheum. : 1582 -1589.

    • Search Google Scholar
  • Klaasen, R., Thurlings, R. M., Wijbrandts, C. A., et al.: The relationship between synovial lymphocyte aggregates and the clinical response to infliximab in rheumatoid arthritis: a prospective study. Arthritis Rheum., 2009, 60, 3217–3224.

    Wijbrandts C. A. , 'The relationship between synovial lymphocyte aggregates and the clinical response to infliximab in rheumatoid arthritis: a prospective study ' (2009 ) 60 Arthritis Rheum. : 3217 -3224.

    • Search Google Scholar
  • Lal, P., Su, Z., Holweg, C. T., et al.: Inflammation and autoantibody markers identify rheumatoid arthritis patients with enhanced clinical benefit following rituximab treatment. Arthritis Rheum., 2011, 63, 3681–3691.

    Holweg C. T. , 'Inflammation and autoantibody markers identify rheumatoid arthritis patients with enhanced clinical benefit following rituximab treatment ' (2011 ) 63 Arthritis Rheum. : 3681 -3691.

    • Search Google Scholar
  • De Vries, M. K., van Eijk, I. C., van der Horst-Bruinsma, I. E., et al.: Erythrocyte sedimentation rate, C-reactive protein level, and serum amyloid a protein for patient selection and monitoring of anti-tumor necrosis factor treatment in ankylosing spondylitis. Arthritis Rheum., 2009, 61, 1484–1490.

    Horst-Bruinsma I. E. , 'Erythrocyte sedimentation rate, C-reactive protein level, and serum amyloid a protein for patient selection and monitoring of anti-tumor necrosis factor treatment in ankylosing spondylitis ' (2009 ) 61 Arthritis Rheum. : 1484 -1490.

    • Search Google Scholar
  • Jones, G., Sebba, A., Gu, J., et al.: Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study. Ann. Rheum. Dis., 2010, 69, 88–96.

    Gu J. , 'Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study ' (2010 ) 69 Ann. Rheum. Dis. : 88 -96.

    • Search Google Scholar
  • Emery, P., Keystone, E., Tony, H. P., et al.: IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial. Ann. Rheum. Dis., 2008, 67, 1516–1523.

    Tony H. P. , 'IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial ' (2008 ) 67 Ann. Rheum. Dis. : 1516 -1523.

    • Search Google Scholar
  • Kojima, T., Yabe, Y., Kaneko, A., et al.: Monitoring C-reactive protein levels to predict favourable clinical outcomes from tocilizumab treatment in patients with rheumatoid arthritis. Mod. Rheumatol., Published online: 2012 October 26. doi: 10.1136/annrheumdis-2011-201230.1

  • Hill, J. A., Southwood, S., Sette, A., et al.: Cutting edge: the conversion of arginine to citrulline allows for a high-affinity peptide interaction with the rheumatoid arthritis-associated HLA-DRB1*0401 MHC class II molecule. J. Immunol., 2003, 171, 538–541.

    Sette A. , 'Cutting edge: the conversion of arginine to citrulline allows for a high-affinity peptide interaction with the rheumatoid arthritis-associated HLA-DRB1*0401 MHC class II molecule ' (2003 ) 171 J. Immunol. : 538 -541.

    • Search Google Scholar
  • Potter, C., Hyrich, K. L., Tracey, A., et al.: Association of rheumatoid factor and anti-cyclic citrullinated peptide positivity, but not carriage of shared epitope or PTPN22 susceptibility variants, with anti-tumour necrosis factor response in rheumatoid arthritis. Ann. Rheum. Dis., 2009, 68, 69–74.

    Tracey A. , 'Association of rheumatoid factor and anti-cyclic citrullinated peptide positivity, but not carriage of shared epitope or PTPN22 susceptibility variants, with anti-tumour necrosis factor response in rheumatoid arthritis ' (2009 ) 68 Ann. Rheum. Dis. : 69 -74.

    • Search Google Scholar
  • Drynda, S., Gloetzner, M., Polter, J.: Prediction of therapy response in anti-TNFa treated RA patients based on the identification of biomarkers. Arthritis Rheum., 2008, 58 (Suppl 9), S211.

    Polter J. , 'Prediction of therapy response in anti-TNFa treated RA patients based on the identification of biomarkers ' (2008 ) 58 Arthritis Rheum. : S211 -.

    • Search Google Scholar
  • Bobbio-Pallavicini, F., Caporali, R., Alpini, C., et al.: High IgA rheumatoid factor levels are associated with poor clinical response to tumour necrosis factor alpha inhibitors in rheumatoid arthritis. Ann. Rheum. Dis., 2007, 66, 302–337.

    Alpini C. , 'High IgA rheumatoid factor levels are associated with poor clinical response to tumour necrosis factor alpha inhibitors in rheumatoid arthritis ' (2007 ) 66 Ann. Rheum. Dis. : 302 -337.

    • Search Google Scholar
  • Isaacs, J. D., Cohen, S. B., Emery, P., et al.: Effect of baseline rheumatoid factor and anticitrullinated peptide antibody serotype on rituximab clinical response: a meta-analysis. Ann. Rheum. Dis., 2012, 72, 329–336.

    Emery P. , 'Effect of baseline rheumatoid factor and anticitrullinated peptide antibody serotype on rituximab clinical response: a meta-analysis ' (2012 ) 72 Ann. Rheum. Dis. : 329 -336.

    • Search Google Scholar
  • Emery, P., Fleischmann, R., Filipowicz-Sosnowska, A., et al.: The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum., 2006, 54, 1390–1400.

    Filipowicz-Sosnowska A. , 'The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial ' (2006 ) 54 Arthritis Rheum. : 1390 -1400.

    • Search Google Scholar
  • Cohen, S. B., Emery, P., Greenwald, M. W., et al.: Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum., 2006, 54, 2793–2806.

    Greenwald M. W. , 'Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks ' (2006 ) 54 Arthritis Rheum. : 2793 -2806.

    • Search Google Scholar
  • Cambridge, G., Stohl, W., Leandro, M. J., et al.: Circulating levels of B lymphocyte stimulator in patients with rheumatoid arthritis following rituximab treatment: relationships with B cell depletion, circulating antibodies, and clinical relapse. Arthritis Rheum., 2006, 54, 723–732.

    Leandro M. J. , 'Circulating levels of B lymphocyte stimulator in patients with rheumatoid arthritis following rituximab treatment: relationships with B cell depletion, circulating antibodies, and clinical relapse ' (2006 ) 54 Arthritis Rheum. : 723 -732.

    • Search Google Scholar
  • Fabris, M., Quartuccio, L., Vital, E., et al.: The TTTT B lymphocyte stimulator promoter haplotype is associated with good response to rituximab therapy in seropositive rheumatoid arthritis resistant to tumor necrosis factor blockers. Arthritis Rheum., 2012, 65, 88–97.

    Vital E. , 'The TTTT B lymphocyte stimulator promoter haplotype is associated with good response to rituximab therapy in seropositive rheumatoid arthritis resistant to tumor necrosis factor blockers ' (2012 ) 65 Arthritis Rheum. : 88 -97.

    • Search Google Scholar
  • Benucci, M., Manfredi, M., Puttini, P. S., et al.: Predictive factors of response to rituximab therapy in rheumatoid arthritis: What do we know today?. Autoimmun. Rev., 2010, 9, 801–803.

    Puttini P. S. , 'Predictive factors of response to rituximab therapy in rheumatoid arthritis: What do we know today? ' (2010 ) 9 Autoimmun. Rev. : 801 -803.

    • Search Google Scholar
  • Furie, R., Stohl, W., Ginzler, E. M., et al.: Biologic activity and safety of belimumab, a neutralizing anti-B-lymphocyte stimulator (BLyS) monoclonal antibody: a phase I trial in patients with systemic lupus erythematosus. Arthritis Res. Ther., 2008, 10, R109.

    Ginzler E. M. , 'Biologic activity and safety of belimumab, a neutralizing anti-B-lymphocyte stimulator (BLyS) monoclonal antibody: a phase I trial in patients with systemic lupus erythematosus ' (2008 ) 10 Arthritis Res. Ther. : R109 -.

    • Search Google Scholar
  • Hueber, W., Tomooka, B. H., Batliwalla, F., et al.: Blood autoantibody and cytokine profiles predict response to anti-tumor necrosis factor therapy in rheumatoid arthritis. Arthritis Res. Ther., 2009, 11, R76.

    Batliwalla F. , 'Blood autoantibody and cytokine profiles predict response to anti-tumor necrosis factor therapy in rheumatoid arthritis ' (2009 ) 11 Arthritis Res. Ther. : R76 -.

    • Search Google Scholar
  • Ferraccioli, G., Tolusso, B., Bobbio-Pallavicini, F., et al.: Biomarkers predictors of good EULAR response to B cell depletion therapy (BCDT) in seropositive rheumatoid arthritis patients. Arthritis Rheum., 2010, 62 (Suppl.), 1098.

    Bobbio-Pallavicini F. , 'Biomarkers predictors of good EULAR response to B cell depletion therapy (BCDT) in seropositive rheumatoid arthritis patients ' (2010 ) 62 Arthritis Rheum. : 1098 -.

    • Search Google Scholar
  • Simkovics, E., Gál, I., Szekanecz, Z.: Pharmacogenetics and pharmacogenomics in rheumatology. [Farmakogenetika és farmakogenomika a reumatológiában.] Magyar Reumatol., 2007, 48, 20–29. [Hungarian]

    Szekanecz Z. , 'Pharmacogenetics and pharmacogenomics in rheumatology. [Farmakogenetika és farmakogenomika a reumatológiában.] ' (2007 ) 48 Magyar Reumatol. : 20 -29.

    • Search Google Scholar
  • Soós, B., Meskó, B., Póliska, S., et al.: Pharmacogenetics and pharmacogenomics of rheumatoid arthritis. II. Pharmacogenetics and pharmacogenomics. [A rheumatoid arthritis genetikája és genomikája. II. Farmakogenetika és farmakogenomika.] Immunol. Szemle, 2013. In press. [Hungarian]

  • Szekanecz, Z.: Pharmacogenomics and biologic therapy. [Farmakogenomika és biológiai terápia.] Figyelő, 2011, I, 4–6. [Hungarian]

    Szekanecz Z. , 'Pharmacogenomics and biologic therapy. [Farmakogenomika és biológiai terápia.] ' (2011 ) I Figyelő : 4 -6.

    • Search Google Scholar
  • Davila, L., Ranganathan, P.: Pharmacogenetics: implications for therapy in rheumatic diseases. Nat. Rev. Rheumatol., 2011, 7, 537–550.

    Ranganathan P. , 'Pharmacogenetics: implications for therapy in rheumatic diseases ' (2011 ) 7 Nat. Rev. Rheumatol. : 537 -550.

    • Search Google Scholar
  • Verweij, C. L.: Pharmacogenetics: Anti-TNF therapy in RA – towards personalized medicine?. Nat. Rev. Rheumatol., 2011, 7, 136–138.

    Verweij C. L. , 'Pharmacogenetics: Anti-TNF therapy in RA – towards personalized medicine? ' (2011 ) 7 Nat. Rev. Rheumatol. : 136 -138.

    • Search Google Scholar
  • Bradford, L. D.: CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants. Pharmacogenomics, 2002, 3, 229–243.

    Bradford L. D. , 'CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants ' (2002 ) 3 Pharmacogenomics : 229 -243.

    • Search Google Scholar
  • Van Kalken, C. K., Broxterman, H. J., Pinedo, H. M., et al.: Cortisol is transported by the multidrug resistance gene product P-glycoprotein. Br. J. Cancer, 1993, 67, 284–289.

    Pinedo H. M. , 'Cortisol is transported by the multidrug resistance gene product P-glycoprotein ' (1993 ) 67 Br. J. Cancer : 284 -289.

    • Search Google Scholar
  • Hoffmeyer, S., Burk, O., von Richter, O., et al.: Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc. Natl. Acad. Sci. USA, 2000, 97, 3473–3478.

    Richter O. , 'Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo ' (2000 ) 97 Proc. Natl. Acad. Sci. USA : 3473 -3478.

    • Search Google Scholar
  • Ulrich, C. M., Yasui, Y., Storb, R., et al.: Pharmacogenetics of methotrexate: toxicity among marrow transplantation patients varies with the methylenetetrahydrofolate reductase C677T polymorphism. Blood, 2001, 98, 231–234.

    Storb R. , 'Pharmacogenetics of methotrexate: toxicity among marrow transplantation patients varies with the methylenetetrahydrofolate reductase C677T polymorphism ' (2001 ) 98 Blood : 231 -234.

    • Search Google Scholar
  • Lee, Y. H., Song, G. G.: Associations between the C677T and A1298C polymorphisms of MTHFR and the efficacy and toxicity of methotrexate in rheumatoid arthritis: a meta-analysis. Clin. Drug. Investig., 2010, 30, 101–108.

    Song G. G. , 'Associations between the C677T and A1298C polymorphisms of MTHFR and the efficacy and toxicity of methotrexate in rheumatoid arthritis: a meta-analysis ' (2010 ) 30 Clin. Drug. Investig. : 101 -108.

    • Search Google Scholar
  • Berkun, Y., Levartovsky, D., Rubinow, A., et al.: Methotrexate related adverse effects in patients with rheumatoid arthritis are associated with the A1298C polymorphism of the MTHFR gene. Ann. Rheum. Dis., 2004, 63, 1227–1231.

    Rubinow A. , 'Methotrexate related adverse effects in patients with rheumatoid arthritis are associated with the A1298C polymorphism of the MTHFR gene ' (2004 ) 63 Ann. Rheum. Dis. : 1227 -1231.

    • Search Google Scholar
  • Dervieux, T., Kremer, J., Lein, D. O., et al.: Contribution of common polymorphisms in reduced folate carrier and gamma-glutamylhydrolase to methotrexate polyglutamate levels in patients with rheumatoid arthritis. Pharmacogenetics, 2004, 14, 733–739.

    Lein D. O. , 'Contribution of common polymorphisms in reduced folate carrier and gamma-glutamylhydrolase to methotrexate polyglutamate levels in patients with rheumatoid arthritis ' (2004 ) 14 Pharmacogenetics : 733 -739.

    • Search Google Scholar
  • Pawlik, A., Wrzesniewska, J., Fiedorowicz-Fabrycy, I., et al.: The MDR1 3435 polymorphism in patients with rheumatoid arthritis. Int. J. Clin. Pharmacol. Ther., 2004, 42, 496–503.

    Fiedorowicz-Fabrycy I. , 'The MDR1 3435 polymorphism in patients with rheumatoid arthritis ' (2004 ) 42 Int. J. Clin. Pharmacol. Ther. : 496 -503.

    • Search Google Scholar
  • Kumagai, K., Hiyama, K., Oyama, T., et al.: Polymorphisms in the thymidylate synthase and methylenetetrahydrofolate reductase genes and sensitivity to the low-dose methotrexate therapy in patients with rheumatoid arthritis. Int. J. Mol. Med., 2003, 11, 593–600.

    Oyama T. , 'Polymorphisms in the thymidylate synthase and methylenetetrahydrofolate reductase genes and sensitivity to the low-dose methotrexate therapy in patients with rheumatoid arthritis ' (2003 ) 11 Int. J. Mol. Med. : 593 -600.

    • Search Google Scholar
  • Tolusso, B., Pietrapertosa, D., Morelli, A., et al.: IL-1B and IL-1RN gene polymorphisms in rheumatoid arthritis: relationship with protein plasma levels and response to therapy. Pharmacogenomics, 2006, 7, 683–695.

    Morelli A. , 'IL-1B and IL-1RN gene polymorphisms in rheumatoid arthritis: relationship with protein plasma levels and response to therapy ' (2006 ) 7 Pharmacogenomics : 683 -695.

    • Search Google Scholar
  • Kumagai, S., Komada, F., Kita, T., et al.: N-acetyltransferase 2 genotype-related efficacy of sulfasalazine in patients with rheumatoid arthritis. Pharm. Res., 2004, 21, 324–329.

    Kita T. , 'N-acetyltransferase 2 genotype-related efficacy of sulfasalazine in patients with rheumatoid arthritis ' (2004 ) 21 Pharm. Res. : 324 -329.

    • Search Google Scholar
  • Clunie, G. P., Lennard, L.: Relevance of thiopurine methyltransferase status in rheumatology patients receiving azathioprine. Rheumatology (Oxford), 2004, 43, 13–18.

    Lennard L. , 'Relevance of thiopurine methyltransferase status in rheumatology patients receiving azathioprine ' (2004 ) 43 Rheumatology (Oxford) : 13 -18.

    • Search Google Scholar
  • Kang, C. P., Lee, K. W., Yoo, D. H., et al.: The influence of a polymorphism at position –857 of the tumour necrosis factor alpha gene on clinical response to etanercept therapy in rheumatoid arthritis. Rheumatology (Oxford), 2005, 44, 547–552.

    Yoo D. H. , 'The influence of a polymorphism at position –857 of the tumour necrosis factor alpha gene on clinical response to etanercept therapy in rheumatoid arthritis ' (2005 ) 44 Rheumatology (Oxford) : 547 -552.

    • Search Google Scholar
  • Bowes, J. D., Potter, C., Gibbons, L. J., et al.: Investigation of genetic variants within candidate genes of the TNFRSF1B signalling pathway on the response to anti-TNF agents in a UK cohort of rheumatoid arthritis patients. Pharmacogenet. Genomics, 2009, 19, 319–323.

    Gibbons L. J. , 'Investigation of genetic variants within candidate genes of the TNFRSF1B signalling pathway on the response to anti-TNF agents in a UK cohort of rheumatoid arthritis patients ' (2009 ) 19 Pharmacogenet. Genomics : 319 -323.

    • Search Google Scholar
  • Potter, C., Cordell, H. J., Barton, A., et al.: Association between anti-tumour necrosis factor treatment response and genetic variants within the TLR and NF{kappa}B signalling pathways. Ann. Rheum. Dis., 2010, 69, 1315–1320.

    Barton A. , 'Association between anti-tumour necrosis factor treatment response and genetic variants within the TLR and NF{kappa}B signalling pathways ' (2010 ) 69 Ann. Rheum. Dis. : 1315 -1320.

    • Search Google Scholar
  • Radstake, T. R., Petit, E., Pierlot, C., et al.: Role of Fcgamma receptors IIA, IIIA, and IIIB in susceptibility to rheumatoid arthritis. J. Rheumatol., 2003, 30, 926–933.

    Pierlot C. , 'Role of Fcgamma receptors IIA, IIIA, and IIIB in susceptibility to rheumatoid arthritis ' (2003 ) 30 J. Rheumatol. : 926 -933.

    • Search Google Scholar
  • Tutuncu, Z., Kavanaugh, A., Zvaifler, N., et al.: Fcgamma receptor type IIIA polymorphisms influence treatment outcomes in patients with inflammatory arthritis treated with tumor necrosis factor alpha-blocking agents. Arthritis Rheum., 2005, 52, 2693–2696.

    Zvaifler N. , 'Fcgamma receptor type IIIA polymorphisms influence treatment outcomes in patients with inflammatory arthritis treated with tumor necrosis factor alpha-blocking agents ' (2005 ) 52 Arthritis Rheum. : 2693 -2696.

    • Search Google Scholar
  • Coulthard, L. R., Taylor, J. C., Eyre, S., et al.: Genetic variants within the MAP kinase signalling network and anti-TNF treatment response in rheumatoid arthritis patients. Ann. Rheum. Dis., 2010, 70, 98–103.

    Eyre S. , 'Genetic variants within the MAP kinase signalling network and anti-TNF treatment response in rheumatoid arthritis patients ' (2010 ) 70 Ann. Rheum. Dis. : 98 -103.

    • Search Google Scholar
  • Fabris, M., Quartuccio, L., Lombardi, S., et al.: The CC homozygosis of the –174G>C IL-6 polymorphism predicts a lower efficacy of rituximab therapy in rheumatoid arthritis. Autoimmun. Rev., 2012, 11, 315–320.

    Lombardi S. , 'The CC homozygosis of the –174G>C IL-6 polymorphism predicts a lower efficacy of rituximab therapy in rheumatoid arthritis ' (2012 ) 11 Autoimmun. Rev. : 315 -320.

    • Search Google Scholar
  • Danila, M. I., Hughes, L. B., Bridges, S. L.: Pharmacogenetics of etanercept in rheumatoid arthritis. Pharmacogenomics, 2008, 9, 1011–1015.

    Bridges S. L. , 'Pharmacogenetics of etanercept in rheumatoid arthritis ' (2008 ) 9 Pharmacogenomics : 1011 -1015.

    • Search Google Scholar
  • Koczan, D., Drynda, S., Hecker, M., et al.: Molecular discrimination of responders and nonresponders to anti-TNF alpha therapy in rheumatoid arthritis by etanercept. Arthritis Res. Ther., 2008, 10, R50.

    Hecker M. , 'Molecular discrimination of responders and nonresponders to anti-TNF alpha therapy in rheumatoid arthritis by etanercept ' (2008 ) 10 Arthritis Res. Ther. : R50 -.

    • Search Google Scholar
  • Julià, A., Erra, A., Palacio, C., et al.: An eight-gene blood expression profile predicts the response to infliximab in rheumatoid arthritis. PLoS ONE, 2009, 4, e7556.

    Palacio C. , 'An eight-gene blood expression profile predicts the response to infliximab in rheumatoid arthritis ' (2009 ) 4 PLoS ONE : e7556 -.

    • Search Google Scholar
  • Lequerré, T., Gauthier-Jauneau, A. C., Bansard, C., et al.: Gene profiling in white blood cells predicts infliximab responsiveness in rheumatoid arthritis. Arthritis Res. Ther., 2006, 8, R105.

    Bansard C. , 'Gene profiling in white blood cells predicts infliximab responsiveness in rheumatoid arthritis ' (2006 ) 8 Arthritis Res. Ther. : R105 -.

    • Search Google Scholar
  • Plant, D., Bowes, J., Potter, C., et al.: Genome-wide association study of genetic predictors of anti-tumor necrosis factor treatment efficacy in rheumatoid arthritis identifies associations with polymorphisms at seven loci. Arthritis Rheum., 2010, 63, 645–653.

    Potter C. , 'Genome-wide association study of genetic predictors of anti-tumor necrosis factor treatment efficacy in rheumatoid arthritis identifies associations with polymorphisms at seven loci ' (2010 ) 63 Arthritis Rheum. : 645 -653.

    • Search Google Scholar
  • Vosslamber, S., Raterman, H. G., van der Pouw Kraan, T. C., et al.: Pharmacological induction of interferon type I activity following treatment with rituximab determines clinical response in rheumatoid arthritis. Ann. Rheum. Dis., 2011, 70, 1153–1159.

    Pouw Kraan T. C. , 'Pharmacological induction of interferon type I activity following treatment with rituximab determines clinical response in rheumatoid arthritis ' (2011 ) 70 Ann. Rheum. Dis. : 1153 -1159.

    • Search Google Scholar
  • Mesko, B., Poliska, S., Szamosi, S., et al.: Peripheral blood gene expression and IgG glycosylation profiles as markers of tocilizumab treatment in rheumatoid arthritis. J. Rheumatol., 2012, 39, 916–928.

    Szamosi S. , 'Peripheral blood gene expression and IgG glycosylation profiles as markers of tocilizumab treatment in rheumatoid arthritis ' (2012 ) 39 J. Rheumatol. : 916 -928.

    • Search Google Scholar
  • Badot, V., Galant, C., Nzeusseu Toukap, A., et al.: Gene expression profiling in the synovium identifies a predictive signature of absence of response to adalimumab therapy in rheumatoid arthritis. Arthritis Res. Ther., 2009, 11, R57.

    Nzeusseu Toukap A. , 'Gene expression profiling in the synovium identifies a predictive signature of absence of response to adalimumab therapy in rheumatoid arthritis ' (2009 ) 11 Arthritis Res. Ther. : R57 -.

    • Search Google Scholar